openPR Logo
Press release

Gene Therapy for Rare Diseases Market Size Growth Forecast 2025-33 | AAV Vectors, CRISPR & Biotech Innovations

08-04-2025 02:01 PM CET | Health & Medicine

Press release from: DataM Intelligence 4Market Research LLP

Gene Therapy For Rare Disease

Gene Therapy For Rare Disease

Gene Therapy for Rare Disease Market Size reached US$3.01 Billion in 2024 and is expected to reach US$24.54 Billion by 2033, growing at a CAGR of 26.5% during the forecast period 2025-2033, according to DataM Intelligence. This growth is propelled by advances in manufacturing technologies, including plug-and-play adeno-associated virus (AAV) serotype production and standardization of analytical and bioanalytical methods, which enhance the efficiency and scalability of gene therapies.

Download your FREE sample report: https://www.datamintelligence.com/download-sample/gene-therapy-for-rare-disease-market?jd

Emerging opportunities stem from the broadening rare disease pipeline, ongoing innovation in delivery vectors, and growing biotech collaborations aimed at expanding gene therapy indications. Regulatory facilitation and governmental incentives supporting orphan drug development also foster market confidence and accelerate therapy commercialization. Leading players in this market include Novartis (Zolgensma), Roche/Genentech, Biomarin, Sarepta Therapeutics, Bluebird Bio, CSL Behring, and Vertex Pharmaceuticals.

Notable Collaborations and Acquisitions Redefining the Gene Therapy for Rare Diseases Market Outlook in 2025

1. AstraZeneca (Alexion) acquisition of Pfizer's gene therapy portfolio in May 2025: AstraZeneca's rare disease group Alexion completed a purchase and license agreement for a portfolio of preclinical rare disease gene therapy programs and enabling technologies from Pfizer. The deal cost up to $1 billion, including tiered royalties, and strengthened AstraZeneca's genomic medicine efforts by adding several novel adeno-associated virus (AAV) capsids proven effective for gene delivery and gene editing.

2. Castle Creek Biosciences financing and expansion in April 2025: Castle Creek, a rare disease-focused gene therapy company, achieved critical clinical milestones in 2025 (such as D-Fi for recessive dystrophic epidermolysis bullosa). Supported by a $75 million royalty financing from Ligand Pharmaceuticals, Castle Creek is accelerating its pipeline and expanding R&D capabilities for both ex vivo and in vivo gene therapies targeting rare metabolic and genetic disorders.

3. Bristol Myers Squibb acquisition of 2seventy bio in March 2025: BMS acquired 2seventy bio, a bluebird bio spin-off focused on gene therapies for rare diseases, for approximately $286 million. This deal expanded BMS's portfolio with innovative gene therapy candidates and solidified its position in the rare genetic disorder treatment landscape.

Innovative Technological Advancements Revolutionizing the Gene Therapy for Rare Diseases Sector in 2025

• Viral Vector Innovations: Improvements in adeno-associated virus (AAV) serotypes with higher tissue tropism and reduced immunogenicity are expanding the range of treatable rare diseases and improving safety profiles. Plug-and-play manufacturing processes and cell suspension technologies increase scalability and reduce production costs.

• Gene Editing Technologies: CRISPR-Cas9 and base editing approaches are being applied to correct mutations precisely, with therapies like exagamglogene autotemcel (exa-cel) approved for sickle cell disease and transfusion-dependent beta-thalassemia. Advances in delivery methods and off-target effect mitigation are critical focus areas.

• Single Dose and Durable Efficacy: Many approved gene therapies (e.g., Luxturna for inherited retinal disease, Zolgensma for spinal muscular atrophy, Hemgenix for hemophilia B) demonstrate long-term benefit from a one-time administration, distinguishing gene therapy from chronic treatments and driving market adoption.

• Regulatory and Manufacturing Advances: Simplified regulatory pathways, incentives for rare disease therapies, and increasing partnerships between biotech firms and governments accelerate development and approval. Standardization and automation of manufacturing processes boost reliability and accessibility.

• Expanding Disease Targets: Beyond classical rare monogenic diseases, gene therapy development is extending into rare cancers, metabolic disorders, and neuromuscular conditions, broadening market scope.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=gene-therapy-for-rare-disease-market?jd

Regional Factors Propelling Growth in the Gene Therapy for Rare Diseases Market in 2025

North America dominates the gene therapy market for rare diseases, holding over 56% market share in 2024. This leadership is driven by robust healthcare infrastructure, high investments in research and development, and advanced regulatory frameworks that facilitate faster clinical trial approvals and product commercialization.

Europe holds a strong position supported by a skilled workforce, well-established healthcare systems, and funding initiatives like the European Union's Horizon 2021 program, boosting gene therapy R&D. Countries including Germany, the UK, and France contribute significantly to market development via research collaborations, clinical development, and manufacturing capabilities.

Asia Pacific is the fastest-growing regional market, driven by increasing healthcare investments, expanding infrastructure, and rising prevalence of genetic and rare diseases in populous nations such as China, India, Japan, and South Korea. Government incentives to promote biotechnology and advances in local manufacturing improve market access.

Request for 2 Days FREE Access:
https://www.datamintelligence.com/reports-subscription?jd

✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Pipeline Analysis For Drug Discovery
✅ Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Competitive Landscape

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg?jd

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us:

DataM Intelligence is a leading market research and consulting firm offering end-to-end business solutions from research to strategy consulting. Leveraging industry trends, insights, and extensive data across more than 6,300 reports in over 40 sectors, DataM Intelligence supports over 200 clients across 50+ countries. Our comprehensive research methodologies empower organizations with actionable intelligence to drive growth and innovation.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Gene Therapy for Rare Diseases Market Size Growth Forecast 2025-33 | AAV Vectors, CRISPR & Biotech Innovations here

News-ID: 4131755 • Views:

More Releases from DataM Intelligence 4Market Research LLP

United States Antiemetic Drugs Market to Reach USD 12.07 Billion by 2033, Growing at a CAGR of 5.5% (2025-2033) | Innovations in Combination Therapies and Generic Launches
United States Antiemetic Drugs Market to Reach USD 12.07 Billion by 2033, Growin …
The Global Antiemetic Drugs Market reached US$ 7.47 Billion in 2024 and is expected to reach US$ 12.07 Billion by 2033, growing at a CAGR of 5.5% during the forecast period 2025-2033. The Antiemetic Drugs Market includes medications to prevent or treat nausea and vomiting caused by chemotherapy, motion sickness, or post-operative conditions. Growth is driven by rising cancer therapies, surgical procedures, and gastroenterological disorders. Drug classes include serotonin receptor antagonists,
United States Oxygen Concentrators Market to Reach USD 2.8 Billion by 2031, Growing at a CAGR of 6% (2024-2031) | Rising COPD and Homecare Adoption Drive Growth
United States Oxygen Concentrators Market to Reach USD 2.8 Billion by 2031, Grow …
The Global Oxygen Concentrators Market reached US$ 1.7 billion in 2023 and is expected to reach US$ 2.8 billion by 2031, growing at a CAGR of 6% during the forecast period 2024-2031. Oxygen Concentrators supply supplemental oxygen for patients with respiratory illnesses or chronic conditions. Growth is driven by rising COPD, COVID-19 recovery care, and aging populations. Devices range from stationary to portable and home-use systems. Hospitals, clinics, and homecare settings
United States Electrosurgical Generator Market Growth Driven by Minimally Invasive Surgeries and Technological Advancements | Top Companies are B.Braun, Medtronic, Olympus, J and J (DePuy Synthes).
United States Electrosurgical Generator Market Growth Driven by Minimally Invasi …
Electrosurgical Generator Market is expected to grow at a CAGR of 6.87% during the forecast period (2024-2031). Electrosurgical Generators provide controlled electrical energy for cutting, coagulation, and tissue ablation in surgeries. Growth is driven by increasing surgical procedures and demand for minimally invasive techniques. Generators integrate with advanced surgical instruments and monitoring systems. Hospitals, surgical centers, and specialty clinics are key end-users. Technological innovations enhance safety, precision, and energy efficiency. Regulatory
Pet Probiotics Market to Reach USD 7.1 Billion by 2031 | Growth Driven by Rising Pet Ownership and Digestive Health Awareness
Pet Probiotics Market to Reach USD 7.1 Billion by 2031 | Growth Driven by Rising …
Global Pet Probiotics Market reached US$ 4,400 million in 2023 and is expected to reach US$ 7,100 million by 2031, growing with a CAGR of 6.16% during the forecast period 2024-2031. The Pet Probiotics Market includes live microbial supplements that support gut health, immunity, and overall wellness in pets. Growth is driven by increasing pet ownership, awareness of digestive health, and premium pet food demand. Products are available in powders, capsules,

All 5 Releases


More Releases for Gene

DNA and Gene Cloning Services Market Expands with Growing Focus on Complex Gene …
InsightAce Analytic Pvt. Ltd. has announced the publication of a market research report titled "Global DNA and Gene Cloning Services Market by Type of Service Offered (Custom Cloning, Sub-cloning, Gene Synthesis, and Others), Type of Gene (Complex Gene, Standard Gene, and Others), End-User Industry (Pharmaceutical, Academic and R&D, and Biotechnology Companies, and Others)- Market Outlook and Industry Analysis 2034" The DNA and Gene Cloning Services Market Size is valued
Evolving Market Trends In The CRISPR Gene Editing Industry: Innovative Gene Ther …
The CRISPR Gene Editing Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Expected CRISPR Gene Editing Market Size During the Forecast Period? The CRISPR gene editing market has grown exponentially in recent years. It will grow from $2.26 billion in 2024 to $2.88
Cell and Gene Therapy Market Global Analysis By Type (Cell Therapy, Gene Therapy …
Gene and cell therapy uses genes and cells for the treatment of genetic diseases. Genetic diseases are caused by mutations, or errors in genes which can be passed down from one generation to another. Gene therapy aims to treat diseases by using genetic material, or DNA, to manipulate a patient's cells by replacing, changing or introducing genome into cells- either internally or externally. Cell therapy aims to treat diseases by
Competitive and Opportunities Analysis of Gene Therapy Market of Gene Therapy Ma …
Global Gene Therapy Market accounted for US$ 2.05 billion in 2020 and is estimated to be US$ 12.29 billion by 2030 and is anticipated to register a CAGR of 19.8%. Gene therapy means fixing a working gene to an individual who features a damaged gene. The European Commission has approved this method for one particular treatment. The treatment by the merchandise Glybera uses an epidemic to infect muscle cells with
Genetic Testing Market Size by Growth Opportunities, Top Key Players: GeneDx, In …
Genetic Testing Market Report provides an in-depth analysis of the overall market, The ripple effect of Coronavirus-Covid19 on the market needs to become part of strategy discussions to emerge strong. The report focuses on major key players, production details, their application, countries and also analyzes the global and key regions market potential and advantage, opportunity, and challenge, restraints, and risks. The Top players Covered in report are GeneDx, Invitae, Pathway Genomics,
Gene Synthesis Market by Top Manufacturers - Gene script, Gene Art (Thermofische …
The "Gene Synthesis Market" report Added by "Big Market Research", enumerates information about the industry in terms of market share, market size, revenue forecasts, and regional outlook. The report further illustrates competitive insights of key players in the business vertical followed by an overview of their diverse portfolios and growth strategies. In the Gene Synthesis Market 2018 research report professionals describe the different facets of the industry with a specific goal